Randomized comparison of Tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B

Gastroenterology

Volumn 146, Issue 4, 2014, Pages 980-988.e1

  Fung, Scott ^a   Kwan, Peter ^b   Fabri, Milotka ^c   Horban, Andrzej ^d   Pelemis, Mijomir ^e   Hann, Hie Won ^f   Gurel, Selim ^g   Caruntu, Florin A ^h   Flaherty, John F ⁱ   Massetto, Benedetta ⁱ   Dinh, Phillip ⁱ   Corsa, Amoreena ⁱ   Subramanian, G Mani ⁱ   McHutchison, John G ⁱ   Husa, Petr ^j   Gane, Edward ^k  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF NOVI SAD   (Serbia)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e UNIVERSITY OF BELGRADE   (Serbia)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g ULUDAG UNIVERSITY   (Turkey)

^h NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Romania)

ⁱ GILEAD SCIENCES   (United States)

^j UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^k AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

HBV DNA; Hepatitis B e Antigen; Renal Function; Viral Suppression

Indexed keywords

ALANINE AMINOTRANSFERASE; DNA; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BONE DENSITY; BONE PAIN; BRONCHOPNEUMONIA; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; FEMALE; FLANK PAIN; GASTROINTESTINAL HEMORRHAGE; GENOTYPE; HEART ARREST; HEPATITIS B; HEPATITIS B VIRUS; HIP; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEROCONVERSION; SOMNOLENCE; SPINE; TREATMENT DURATION; VIRUS MUTATION;

HBV DNA; HEPATITIS B E ANTIGEN; RENAL FUNCTION; VIRAL SUPPRESSION;

ADENINE; ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DEOXYCYTIDINE; DNA, VIRAL; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; EUROPE; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEW ZEALAND; NORTH AMERICA; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84896491915     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.12.028     Document Type: Article

References (38)

1. Y.F. Liaw, N. Leung, and J.H. Kao et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 2008 263 283
2. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
3. C.L. Lai, J. Dienstag, and E. Schiff et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B Clin Infect Dis 36 2003 687 696
4. N.W. Leung, C.L. Lai, and T.T. Chang et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy Hepatology 33 2001 1527 1532
5. Y.F. Liaw, J.J. Sung, and W.C. Chow et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 2004 1521 1531
6. A.S. Lok, F. Zoulim, and S. Locarnini et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management Hepatology 46 2007 254 265
7. P. Lampertico, M. Vigano, and E. Manenti et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine Hepatology 42 2005 1414 1419
8. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661-622
9. R.P. Perrillo, H.W. Hann, and E. Schiff et al. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance Hepatol Int 5 2011 654 663
10. W.K. Seto, K. Liu, and J. Fung et al. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir Antivir Ther 17 2012 1255 1262
11. M.S. Choi, and B.C. Yoo Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines Gut Liver 4 2010 15 24
12. C.S. Coffin, S.K. Fung, and M.M. Ma et al. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines Can J Gastroenterol 26 2012 917 938
13. F. van Bömmel, R.A. de Man, and H. Wedemeyer et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues Hepatology 51 2010 73 80
14. C.J. Baldick, B.J. Eggers, and J. Fang et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response J Hepatol 48 2008 895 902
15. D.R. Langley, A.W. Walsh, and C.J. Baldick et al. Inhibition of hepatitis B virus polymerase by entecavir J Virol 81 2007 3992 4001
16. T.T. Chang, R.G. Gish, and S.J. Hadziyannis et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients Gastroenterology 129 2005 1198 1209
17. M. Sherman, C. Yurdaydin, and J. Sollano et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B Gastroenterology 130 2006 2039 2049
18. D.J. Tenney, R.E. Rose, and C.J. Baldick et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy Hepatology 49 2009 1503 1514
19. E.J. Heathcote, P. Marcellin, and M. Buti et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
20. P. Marcellin, E. Gane, and M. Buti et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study Lancet 381 2013 468 475
21. P. Marcellin, E.J. Heathcote, and M. Buti et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
22. W.E. Delaney, A.S. Ray, and H. Yang et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus Antimicrob Agents Chemother 50 2006 2471 2477
23. H. Yang, X. Qi, and A. Sabogal et al. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV Antivir Ther 10 2005 625 633
24. H.W. Hann, H.B. Chae, and S.R. Dunn Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV) Hepatol Int 2 2008 244 249
25. A. Kuo, J.L. Dienstag, and R.T. Chung Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B Clin Gastroenterol Hepatol 2 2004 266 272
26. S.J. Patterson, J. George, and S.I. Strasser et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B Gut 60 2011 247 254
27. Tsai N, Gane E, Weilert F, et al. Five years of treatment with tenofovir disoproxil fumarate (TDF) for chronic hepatitis lamivudune-experienced patients is associated with sustained viral suppression and histological improvement. 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL). February 16-19, 2012; Taipei, Taiwan.
28. K. Borroto-Esoda, N. Parkin, and M.D. Miller A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine Antivir Chem Chemother 18 2007 297 300
29. K.M. Kitrinos, A. Corsa, and Y. Liu et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B Hepatology 2013 Aug 12 [Epub ahead of print]
30. Y. Zhu, M. Curtis, and K. Borroto-Esoda HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays J Virol Methods 173 2011 340 346
31. T. Berg, F. Zoulim, and B. Moeller et al. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients J Hepatol 2013 Nov 29 [Epub ahead of print]
32. A.S. Lok, H. Trinh, and G. Carosi et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B Gastroenterology 143 2012 619 628.e611
33. M. Sherman, C. Yurdaydin, and H. Simsek et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks Hepatology 48 2008 99 108
34. Jacobson IM, Marcellin P, Buti M. Factors associated with persistently elevated ALT in chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 9-13, 2012; Boston, MA. Abstract 411.
35. J.E. Gallant, S. Staszewski, and A.L. Pozniak et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial JAMA 292 2004 191 201
36. G.A. McComsey, D. Kitch, and E.S. Daar et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202 J Infect Dis 203 2011 1791 1801
37. F.J. Gallego-Rojo, J.L. Gonzalez-Calvin, and M. Munoz-Torres et al. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis Hepatology 28 1998 695 699
38. I. Schiefke, A. Fach, and M. Wiedmann et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection World J Gastroenterol 11 2005 1843 1847